KR20220122602A - 자폐 스펙트럼 장애의 증상을 치료하는 방법 - Google Patents

자폐 스펙트럼 장애의 증상을 치료하는 방법 Download PDF

Info

Publication number
KR20220122602A
KR20220122602A KR1020227017060A KR20227017060A KR20220122602A KR 20220122602 A KR20220122602 A KR 20220122602A KR 1020227017060 A KR1020227017060 A KR 1020227017060A KR 20227017060 A KR20227017060 A KR 20227017060A KR 20220122602 A KR20220122602 A KR 20220122602A
Authority
KR
South Korea
Prior art keywords
treatment
patient
points
asd
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227017060A
Other languages
English (en)
Korean (ko)
Inventor
마이클 우드
제임스 릴리
Original Assignee
맵라이트 세라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 맵라이트 세라퓨틱스, 인크. filed Critical 맵라이트 세라퓨틱스, 인크.
Publication of KR20220122602A publication Critical patent/KR20220122602A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227017060A 2019-10-23 2020-10-23 자폐 스펙트럼 장애의 증상을 치료하는 방법 Pending KR20220122602A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962925023P 2019-10-23 2019-10-23
US62/925,023 2019-10-23
US202063011715P 2020-04-17 2020-04-17
US63/011,715 2020-04-17
PCT/US2020/057133 WO2021081376A1 (en) 2019-10-23 2020-10-23 Methods of treating the symptoms of autism spectrum disorder

Publications (1)

Publication Number Publication Date
KR20220122602A true KR20220122602A (ko) 2022-09-02

Family

ID=75620321

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017060A Pending KR20220122602A (ko) 2019-10-23 2020-10-23 자폐 스펙트럼 장애의 증상을 치료하는 방법

Country Status (17)

Country Link
US (1) US20220387396A1 (https=)
EP (2) EP4681714A3 (https=)
JP (2) JP7766026B2 (https=)
KR (1) KR20220122602A (https=)
CN (1) CN114901270A (https=)
AU (1) AU2020370479A1 (https=)
CA (1) CA3158781A1 (https=)
DK (1) DK4048249T3 (https=)
ES (1) ES3056138T3 (https=)
FI (1) FI4048249T3 (https=)
HR (1) HRP20251489T1 (https=)
IL (1) IL292367B1 (https=)
LT (1) LT4048249T (https=)
MX (2) MX2022004910A (https=)
PT (1) PT4048249T (https=)
SI (1) SI4048249T1 (https=)
WO (1) WO2021081376A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022079307A1 (en) * 2020-10-16 2022-04-21 Purposeful Ike Compositions and uses thereof
US20240189240A1 (en) * 2021-03-25 2024-06-13 Maplight Therapeutics, Inc. Pharmaceutical compositions comprising zolmitriptan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236787B2 (en) * 2008-12-09 2012-08-07 Synthonics, Inc. Frequency modulated drug delivery (FMDD)
BR112016027096B1 (pt) * 2014-05-19 2023-04-11 Northeastern University Composições farmacêuticas e compostos de receptores-alvo de serotonina e seus usos
HUE059559T2 (hu) * 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
KR102534545B1 (ko) * 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법

Also Published As

Publication number Publication date
ES3056138T3 (en) 2026-02-18
WO2021081376A1 (en) 2021-04-29
US20220387396A1 (en) 2022-12-08
EP4681714A3 (en) 2026-04-15
EP4048249A1 (en) 2022-08-31
CN114901270A (zh) 2022-08-12
IL292367B1 (en) 2026-04-01
HRP20251489T1 (hr) 2026-01-02
LT4048249T (lt) 2026-02-10
JP2026031955A (ja) 2026-02-25
DK4048249T3 (da) 2025-12-15
MX2022004910A (es) 2022-08-18
AU2020370479A1 (en) 2022-04-28
EP4681714A2 (en) 2026-01-21
JP7766026B2 (ja) 2025-11-07
PT4048249T (pt) 2025-12-02
EP4048249B1 (en) 2025-09-03
JP2022554090A (ja) 2022-12-28
EP4048249A4 (en) 2023-12-13
FI4048249T3 (fi) 2025-12-05
SI4048249T1 (sl) 2026-04-30
MX2025008168A (es) 2025-08-01
CA3158781A1 (en) 2021-04-29
IL292367A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Lanza et al. Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
US20140088083A1 (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
JP2013241463A (ja) 女性性的機能不全の処置におけるテストステロンを含む薬剤の組み合わせ
JP2024524679A (ja) アルツハイマー病の処置方法
US10195165B2 (en) Methods of treating Prader-Willi syndrome
EP3125902A2 (en) Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants
KR20240038980A (ko) 파킨슨병 및/또는 루이체 질환 또는 장애(들)의 치료 방법
WO2020028810A1 (en) Compositions and methods for treating brain-gut disorders
RU2844953C1 (ru) Способы лечения симптомов расстройства аутистического спектра
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
KR20240165982A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
HK40080588A (en) Methods of treating the symptoms of autism spectrum disorder
HK40080588B (en) Methods of treating the symptoms of autism spectrum disorder
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Herlihy Investigation of Depressive-Like Behavior and Non-Invasive Focused Ultrasound Efficacy in a Rodent Model of Parkinson’s Disease
WO2025145241A1 (en) Treatment of gut-brain interaction disorders
CA3257705A1 (en) TREATMENT OF PATIENTS RESISTANT TO ANTIDEPRESSANTS
Bernard et al. Tourette syndrome and the spectrum of neurodevelopmental tic disorders
Makkonen Childhood autism: aspects of growth factors and monoaminergic transporters in etiopathogenesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000